MBBS, FRCA, FRCP, FJFICM
Charlie is a Senior Intensive Care Specilaist at University Hospital Geelong, and the President of the College of Intensive Care Medicine
He undertook medical training at St Bartholomew’s hospital in London. After training as a physician he converted to anaesthesia and finally settled on becoming an intensive care specialist. After working in Hong Kong he came to Australia, initially working as Director of Intensive Care at the Repatriation Hospital in Melbourne. In 1991 he became Director of Intensive Care in Geelong. He has had extensive invovlement with the College of Intensive Care Medicine, serving as an Examiner, and an Executive Member since 2003. In 2008 he stepped down as Director of ICU at UHG to concentrate on his diverse medical interests.
Charlies careers include;
- Former President of the College of Intensive Care Medicine
- Regional clinical lead for the Respecting Patient Choices program
- Originator of the ‘MyValues’ approach to advance care planning
- Former Director ICU, Bawon Health
Charlie has published a number of papers and books on medicine and was featured on the ABC in the film ‘In the End’, and 'Insight'.
Respecting Patient Choices
Latest news:
-
Thursday, April 8, 2021 - 16:13
JAMA BACLOREA High-dose baclofen reduced agitation-related events in adult patients with unhealthy alcohol use requiring mechanical ventilation. However secondary outcomes of deeper sedation, longer duration of mechanical ventilation, prolonged ICU care = more research
Tuesday, April 6, 2021 - 14:25JAMA Mechanical ventilation weaning practices vary internationally, regard to the use of protocols, screening for and conducting SBTs, adjustment of ventilator support, and the responsibility of clinicians involved in weaning
Tuesday, April 6, 2021 - 12:01JAMA HENIVOT Trial -Helmet NIV vs HFNC for critically ill patients with mod-severe hypoxemic COVID resp failure = no diff in the resp support fee days (28 d). Secondary diff in intubation, lower in helmet group, ie overall no difference in 28-d resp support, but helmet lower proportion of this time intubated.
Friday, February 19, 2021 - 07:30JAMA RCT does not support use of single high dose oral vitamin D3 for treatment of moderate to severe COVID-19 in hospitalized patients. Limitations in design, however, confirms lack of benefit reported in multiple large non-COVID trials in hospital or ICU patients (VIOLET, VITdAL-ICU)
Sunday, February 14, 2021 - 09:30NEJM DePPaRT: 1% of patients with loss of cardiac activity after planned withdrawal of life sustaining therapy have transient resumption of cardiac activity observable by bedside reports and corroborated by ECG and IABP waveform activity. Retrospective waveform review showed resumption of cardiac activity in 14% of patients. The longest period of pulselessness that was followed by resumption of cardiac activity was 4 minutes 20 seconds.